Rosella
Rosella Kendrick, Stourbridge GB
Patent application number | Description | Published |
---|---|---|
20140012215 | SYSTEMS, METHODS, AND DEVICES FOR TREATING A TISSUE SITE ON A MAMMAL HAVING HAIR PROXIMATE THE TISSUE SITE - Systems, methods, and devices are presented for treating a tissue site and managing hair proximate the tissue site. A composition is provided for inhibiting, removing, or weakening hair proximate the tissue site and for providing an improved fluid seal by a flexible film drape over the tissue site. In some example embodiments, a hair-modification agent is disposed at least proximate a peripheral edge of a treatment manifold between a drape and epidermis proximate a tissue site. The hair-modification agent can be configured to flow over imperfections on the epidermis and to form a fluid seal against the epidermis, and can further be configured to at least substantially weaken hair on the epidermis as the hair encounters the hair-modification agent. | 01-09-2014 |
Rosella Malanchin, Cesate IT
Patent application number | Description | Published |
---|---|---|
20140128798 | DELIVERY OF LARGE MOLECULAR WEIGHT BIOLOGICALLY ACTIVE SUBSTANCES - The invention relates generally to intradermal, transdermal, and/or transmembrane delivery of biologically active substances in the epidermis and/or through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular surface, tissue or membrane. The biologically active substances may have a molecular weight no less than about 5.8 kDa to about 2,500 kDa, such as Hyaluronic Acid (HA). The biologically active substances may be deposited in a dermal patch containing a red algae polysaccharide-based matrix, wherein the red algae polysaccharide is an extract of | 05-08-2014 |
Rosella Mechelli, Rome IT
Patent application number | Description | Published |
---|---|---|
20160060718 | EPSTEIN BARR VIRUS GENOTIPIC VARIANTS AND USES THEREOF AS RISK PREDICTORS, BIOMARKERS AND THERAPEUTIC TARGETS IN MULTIPLE SCLEROSIS - The present invention relates to a nucleic acid coding for a variant of the Epstein Barr nuclear antigen 2 (EBNA2) for use as a biomarker for predicting the risk of developing multiple sclerosis and/or for screening and/or for the diagnosis and/or prognosis of multiple sclerosis, and to an in vitro method for predicting the risk of developing and/or for screening for multiple sclerosis and/or for the diagnosis and/or prognosis of multiple sclerosis in a subject, comprising the detection of the presence of said nucleic acid. | 03-03-2016 |
Rosella Ombrato, San Lorerizo Del Vallo IT
Patent application number | Description | Published |
---|---|---|
20090186922 | 2-ARYLINDOLE DERIVATIVES AS NPGES-I INHIBITORS - A 2-arylindole compound substituted in position 5, of formula (I): in which X, Y, Z, W, A, R and R′ have the meanings given in the description, a pharmaceutical composition comprising it, and also intermediate compounds and a preparation process therefor. | 07-23-2009 |
Rosella Ombrato, San Lorenzo Del Vallo (cosenza) IT
Patent application number | Description | Published |
---|---|---|
20100056573 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS - 2-Alkyl-indazole compound and its pharmaceutically acceptable salts of acid addition, method and intermediates for preparing them, a pharmaceutical composition containing them and use of the latter. The 2-alkyl-indazole compound has the following general formula (I) in which R1, R2, R3, R4, R6, R7, X, Y, W, n, p, and m have the meanings stated in the description. | 03-04-2010 |
Rosella Ombrato, San Lorenzo Del Vallo (cs) IT
Patent application number | Description | Published |
---|---|---|
20140378455 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS - 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies. | 12-25-2014 |
20150057294 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS - The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain. | 02-26-2015 |
20160045485 | NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS - The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies. | 02-18-2016 |
Rosella Rizzonelli, Bondo (tn) IT
Patent application number | Description | Published |
---|---|---|
20140190664 | HEAT EXCHANGER - A heat exchanger device ( | 07-10-2014 |